Pleural fluid glucose: A predictor of unsuccessful pleurodesis in a preselected cohort of patients with malignant pleural effusion.

PURPOSE To assess whether exclusion of patients with conditions that could lead to large fluctuations of serum glucose, would increase the accuracy of pleural fluid glucose in predicting pleurodesis outcome in patients with malignant pleural effusion subjected to bleomycin pleurodesis. METHODS A retrospective analysis of 162 patients with recurrent, symptomatic malignant pleural disease was performed. Patients with diabetes mellitus or other causes of hyperglycemia were excluded, as pleural fluid glucose has been reported to be sensitive to serum glucose fluctuations. Assessment of pleurodesis outcome was based on radiologic appearance 30 days post-bleomycin pleurodesis. RESULTS Successful pleurodesis was achieved in 64.8% of patients. Univariate analysis showed that pleural fluid glucose (p<0.001), pH (p<0.001), total proteins (p<0.001), albumin (p<0.001) and cholesterol (p<0.05) were significantly lower in patients with pleurodesis failure, while LDH was significantly higher (p<0.05). Pleural fluid glucose was the only independent predictor of pleurodesis outcome and with a cut-off point of 65 mg/dl had a high sensitivity (90.7%) with an acceptable specificity (76.8%) (p<0.001). The regression model exhibiting the highest predictive accuracy included pleural fluid glucose and albumin (sensitivity 89.3%, specificity 84.5%, p<0.001). Furthermore, a product of glucose and albumin less than 152 could predict pleurodesis failure with 88.9% sensitivity and 82.8% specificity (p<0.001). CONCLUSIONS Pleural glucose levels may reliably predict pleurodesis failure in patients without conditions that could lead to hyperglycemia, and its accuracy can increase if combined with pleural fluid albumin in an-easy-to calculate formula.

[1]  W. C. Ball,et al.  Lactate Dehydrogenase Isoenzymes in Pleural Effusions1 , 2015 .

[2]  Edmund Neville,et al.  Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[3]  A. Musani Treatment options for malignant pleural effusion , 2009, Current opinion in pulmonary medicine.

[4]  M. Metintaş,et al.  Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. , 2008, Lung cancer.

[5]  M. Jantz,et al.  Pathophysiology of the Pleura , 2008, Respiration.

[6]  J. Heffner,et al.  Diagnosis and management of malignant pleural effusions , 2007, Respirology.

[7]  I. Uçgun,et al.  Increased Pleural Fluid Adenosine Deaminase Levels in Patients with Malignant Pleural Effusions: A Potential Predictor of Talc Pleurodesis Outcome , 2007, Lung.

[8]  A. Covey Management of malignant pleural effusions and ascites. , 2005, The journal of supportive oncology.

[9]  G. Hillerdal,et al.  Inflammatory parameters after pleurodesis in recurrent malignant pleural effusions and their predictive value. , 2004, Respiratory medicine.

[10]  A. Tattersfield,et al.  Sex ratio at birth in Masjid-i-Sulaiman (Khozestan province, Iran) , 2002, Occupational and environmental medicine.

[11]  A. Bernard,et al.  Early and late mortality after pleurodesis for malignant pleural effusion. , 2002, The Annals of thoracic surgery.

[12]  S. Sahn,et al.  Management of malignant pleural effusions. , 2001, The European respiratory journal.

[13]  J. Heffner,et al.  Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. , 2000, Chest.

[14]  J. Aparicio,et al.  Malignant Pleural Effusion: Prognostic Factors for Survival and Response to Chemical Pleurodesis in a Series of 120 Cases , 1998, Respiration.

[15]  Y. Aelony,et al.  Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. , 1998, Chest.

[16]  U. Çağırıcı,et al.  Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level. , 1998, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[17]  V. Antony,et al.  Pleurodesis: state of the art. , 1997, The European respiratory journal.

[18]  M. Chuang,et al.  Elastance of the Pleural Space: A Predictor for the Outcome of Pleurodesis in Patients with Malignant Pleural Effusion , 1997, Annals of Internal Medicine.

[19]  J. Castillo,et al.  Failure of talc pleurodesis is associated with increased pleural fibrinolysis. , 1995, American journal of respiratory and critical care medicine.

[20]  V. Foresti Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions. , 1995, Respiration; international review of thoracic diseases.

[21]  F. Rodríguez‐Panadero,et al.  Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. , 1993, Chest.

[22]  J. Koeller,et al.  Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. , 1991, Chest.

[23]  F. Rodríguez‐Panadero,et al.  Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. , 1989, The American review of respiratory disease.

[24]  F. Rodríguez‐Panadero,et al.  Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. , 1989, Chest.

[25]  S. Sahn,et al.  The pathogenesis of low glucose, low pH malignant effusions. , 2015, The American review of respiratory disease.

[26]  Ostrowski Mj,et al.  Intracavitary bleomycin in the management of malignant effusions: a multicenter study. , 1982, Cancer treatment reports.

[27]  J. Bitran,et al.  Intracavitary bleomycin for the control of malignant effusions , 1981, Journal of surgical oncology.

[28]  W. C. Ball,et al.  Lactate dehydrogenase isoenzymes in pleural effusions. , 1973, The American review of respiratory disease.